Correspondence to editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis".
作者信息
Chon Young Eun, Yu Jung Hwan, Kim Seung Up
机构信息
Department of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):e61-e63. doi: 10.3350/cmh.2024.0878. Epub 2024 Oct 15.
Abstract
摘要
相似文献
1
Correspondence to editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):e61-e63. doi: 10.3350/cmh.2024.0878. Epub 2024 Oct 15.
2
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):277-280. doi: 10.3350/cmh.2024.0823. Epub 2024 Oct 11.
3
Towards unification of liver stiffness measurement cutoffs: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):264-267. doi: 10.3350/cmh.2024.0766. Epub 2024 Sep 20.
4
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Clin Mol Hepatol. 2024 Sep;30(Suppl):S117-S133. doi: 10.3350/cmh.2024.0392. Epub 2024 Aug 21.
5
Correspondence to editorial on "Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):e52-e54. doi: 10.3350/cmh.2024.0815. Epub 2024 Sep 24.
6
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
J Hepatol. 2021 Oct;75(4):770-785. doi: 10.1016/j.jhep.2021.04.044. Epub 2021 May 13.
7
A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
Eur Radiol. 2024 Jun;34(6):3882-3888. doi: 10.1007/s00330-023-10441-5. Epub 2023 Nov 21.
8
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
Health Technol Assess. 2023 Jul;27(10):1-115. doi: 10.3310/KGJU3398.
9
Concordance of vibration-controlled transient elastography and magnetic resonance elastography for fibrosis staging in patients with metabolic dysfunction-associated steatotic liver disease.
Eur Radiol. 2025 Mar 30. doi: 10.1007/s00330-025-11533-0.
10
Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease.
Cochrane Database Syst Rev. 2015 Jan 22;1(1):CD010542. doi: 10.1002/14651858.CD010542.pub2.
本文引用的文献
1
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on "Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis".
Clin Mol Hepatol. 2025 Jan;31(1):277-280. doi: 10.3350/cmh.2024.0823. Epub 2024 Oct 11.
2
Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis.
Clin Mol Hepatol. 2024 Sep;30(Suppl):S117-S133. doi: 10.3350/cmh.2024.0392. Epub 2024 Aug 21.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study.
Clin Mol Hepatol. 2024 Apr;30(2):225-234. doi: 10.3350/cmh.2023.0515. Epub 2024 Jan 24.
5
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
Clin Mol Hepatol. 2023 Oct;29(4):831-843. doi: 10.3350/cmh.2023.0277. Epub 2023 Aug 25.
6
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
7
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
8
Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.
Front Med (Lausanne). 2021 Apr 14;8:615978. doi: 10.3389/fmed.2021.615978. eCollection 2021.
Zotero 插件